LEP and inflammatory bowel disease: Due to leptin acting as a proinflammatory adipokine, especially in obese subjects, this peptide is implicated in the pathogenesis of IBD, and therefore leptin antagonists are postulated as a potential therapeutic option for IBD [132,133].